Featured Posters & Presentations
Lyfgenia
Outcomes for initial patient cohorts with up to 33 months of follow-up in the HGB-206 Phase 1 trial.
Authors: Kanter J.
Lyfgenia
Current results of LentiGlobin gene therapy in patients with severe sickle cell disease treated under a refined protocol in the Phase 1 HGB-206 study.
Authors: Tisdale JF.
Lyfgenia
Analysis of RBC properties in patients with SCD Treated with LentiGlobin gene therapy.
Authors: Herbert N.
Lyfgenia
Characterizing the U.S. Population with severe manifestations of sickle cell disease using real-world evidence.
Authors: Paramore C.
Zynteglo
Clinical outcomes of LentiGlobin gene therapy for transfusion-dependent β-thalassemia following completion of the Northstar HGB-204 Study.
Authors: Rasko JE.
Zynteglo
LentiGlobin gene therapy for patients with transfusion-dependent β -thalassemia (TDT ): results from the Phase 3 Northstar-2 and Northstar-3 Studies.
Authors: Locatelli F.